Prenetics Global Reports Record Q4 & FY2025 Results, IM8 Achieves $120M ARR, $171M Liquidity

summarizeSummary

Prenetics Global reported record Q4 and full-year 2025 financial results, driven by its IM8 brand achieving $120 million in annualized recurring revenue within 12 months of launch. The company also completed its strategic transformation, resulting in approximately $171 million in adjusted liquidity and zero debt.

check_boxKey Events

• Record Financial Performance

  Full-year 2025 revenue surged 480% to $92.4 million, with Q4 revenue reaching $36.6 million, up 457.1% year-over-year and 55.2% quarter-over-quarter.

• IM8 Brand Achieves Milestone

  The IM8 premium health and longevity brand reached $120 million in annualized recurring revenue (ARR) by December 2025, just 12 months after launch, contributing $60.1 million to FY2025 revenue.

• Strengthened Balance Sheet

  Following the completion of strategic divestitures, the company boasts approximately $171 million in total adjusted liquidity as of February 15, 2026, with zero outstanding debt.

• Positive Outlook and Guidance

  Prenetics reaffirmed its 2026 IM8 revenue guidance of $180 million to $200 million, targeting $250 million to $300 million in ARR by year-end 2026, and expects to achieve adjusted EBITDA profitability by Q4 2027.

auto_awesomeAnalysis

This filing details a highly successful period for Prenetics Global, marked by exceptional revenue growth and the rapid scaling of its IM8 premium health and longevity brand. The company's strategic divestitures, previously reported on February 17th and January 6th, have significantly strengthened its balance sheet, providing substantial financial capacity for future growth. The reaffirmed strong 2026 guidance for IM8, coupled with a clear path to adjusted EBITDA profitability by Q4 2027, indicates robust operational momentum and a focused strategy. Investors should view these results as a strong validation of the company's strategic shift towards its high-growth consumer health segment.